Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6897451 | 0.96 | KDR (0.93) | KDRTBK1 | |
| SCHEMBL6178074 | 0.91 | KDR (1.00) | KDRTBK1 | |
| SCHEMBL6179134 | 0.89 | KDR (1.00) | KDRTBK1 | |
| SCHEMBL6177027 | 0.89 | KDR (1.00) | KDRTBK1 | |
| SCHEMBL6179016 | 0.88 | KDR (1.00) | KDRTBK1 | |
| SCHEMBL7237182 | 0.87 | KDR (0.84) | KDRTBK1 | |
| SCHEMBL5745318 | 0.86 | KDR (0.76) | KDRTBK1 | |
| SCHEMBL5741891 | 0.85 | KDR (0.75) | KDR | |
| SCHEMBL5742446 | 0.85 | KDR (0.75) | KDR | |
| SCHEMBL5743246 | 0.84 | KDR (0.73) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1404672-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2006-01-18 | — | — | EP | claimed |
| US-6875767-B2 | (5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2005-04-05 | — | — | US | claimed |
| US-6872724-B2 | Polymorphs with tyrosine kinase activity | MERCK & CO., INC. (US) | 2005-03-29 | — | — | US | claimed |
| EP-1404672-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2004-04-07 | — | — | EP | claimed |
| US-20040023979-A1 | Process for making substituted thiazolyl-amino pyridines | ZHAO MATTHEW M (US) | 2004-02-05 | — | — | US | claimed |
| US-20040023981-A1 | Salt forms with tyrosine kinase activity | REN YU (US) | 2004-02-05 | — | — | US | claimed |
| US-20040023978-A1 | Active salt forms with tyrosine kinase activity | REN YU | 2004-02-05 | — | — | US | claimed |
| US-20040023980-A1 | Polymorphs with tyrosine kinase activity | MERCK SHARP & DOHME CORP. | 2004-02-05 | — | — | US | claimed |
| US-20030100567-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2003-05-29 | — | — | US | claimed |
| WO-2003000687-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-01-03 | — | — | WO | claimed |
| EP-1404672-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-6875767-B2 | (5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2005-04-05 | — | — | US | disclosed |
| US-6872724-B2 | Polymorphs with tyrosine kinase activity | MERCK & CO., INC. (US) | 2005-03-29 | — | — | US | disclosed |
| US-6872724-B2 | Polymorphs with tyrosine kinase activity | MERCK & CO., INC. (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1404672-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20040023979-A1 | Process for making substituted thiazolyl-amino pyridines | ZHAO MATTHEW M (US) | 2004-02-05 | — | — | US | disclosed |
| US-20040023981-A1 | Salt forms with tyrosine kinase activity | REN YU (US) | 2004-02-05 | — | — | US | disclosed |
| US-20040023981-A1 | Salt forms with tyrosine kinase activity | REN YU (US) | 2004-02-05 | — | — | US | disclosed |
| US-20030100567-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2003000687-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023981-A1 | Salt forms with tyrosine kinase activity | TEK, MAP3K1, MAP3K2 | KDR 16/4885TBK1 481/4885 |
| US-20040023979-A1 | Process for making substituted thiazolyl-amino pyridines | ERBB2, ERBB4, TYRO3 | KDR 110/4885TBK1 99/4885 |
| US-20040023978-A1 | Active salt forms with tyrosine kinase activity | STAT3, MAP3K1, MAP3K5 | KDR 52/4885TBK1 345/4885 |
| US-20040023980-A1 | Polymorphs with tyrosine kinase activity | KDR, FLT1, FLT4 | KDR 1/4885TBK1 546/4885 |
| US-20030100567-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885TBK1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.